Prademagene zamikeracel

帕基佐壳赛

Report date: 2026/05/20 15:36:43

Base Information

Drug NamePrademagene zamikeracel
Drug Alias NameLZRSE-Col7A1 Engineered Autologous Epidermal SheetsLZRSE-COL7A1Pz-celLEAESGene-corrected skin grafts +[8] 
ClassificationCell and gene therapy > Cell therapy > Somatic cell > Keratinocytes therapyCell and gene therapy > Cell therapy > Source of cells > Skin biopsies-derivedCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vector +[4] 
Mechanisms of ActionCOL7A1 gene transference
TargetsCollagen alpha-1(VII) chain
Therapy Area/IndicationsEpidermolysis Bullosa DystrophicaEpidermolysis Bullosa
Global Approved IndicationsEpidermolysis Bullosa Dystrophica
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2025/04/28
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesStanford UniversityAbeona Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesStanford UniversityAbeona Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsEpidermolysis Bullosa DystrophicaEpidermolysis Bullosa
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBank